Blockchain Registration Transaction Record

Tonix Pharmaceuticals Nears Market Entry with Tonmya for Fibromyalgia Management

Tonix Pharmaceuticals CEO Dr. Seth Lederman announces the completion of the initial phase of an assessment on the U.S. market opportunity for Tonmya, a potential groundbreaking first-line therapy for fibromyalgia management.

The potential approval of Tonmya as a non-opioid, centrally-acting alternative for fibromyalgia management could significantly impact patients' access to safer and non-addictive treatment options. It also has the potential to shift the current market dominance of opioids in fibromyalgia prescription, leading to improved patient outcomes and reduced risks of dependency.